Mind Medicine (MindMed) Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Mind Medicine (MindMed) Inc 公司

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. The Company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Mind Medicine (MindMed) Inc簡介



公司代碼MNMD

公司名稱Mind Medicine (MindMed) Inc

上市日期May 04, 2015

CEOBarrow (Robert B)

員工數量74

證券類型Ordinary Share

年結日May 04

公司地址One World Trade Center

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編10007

電話12122206633

網址https://ir.mindmed.co/

公司代碼MNMD

上市日期May 04, 2015

CEOBarrow (Robert B)

Mind Medicine (MindMed) Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Robert (Rob) Barrow

Chief Executive Officer, Director

518.46K

+320000.00%

Mr. Mark R. Sullivan

Chief Legal Officer, Corporate Secretary

20.08K

-11276.00%

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

17.64K

+5402.00%

Dr. Roger Crystal, M.D.

Independent Director

17.64K

+5402.00%

Mr. David W. (Dave) Gryska

Independent Director

10.62K

-9234.00%

Dr. Daniel R. Karlin, M.D.

Chief Medical Officer

--

Mr. Andreas R. Krebs

Independent Vice Chairman of the Board

--

Ms. Carol A. Vallone

Independent Chairman of the Board

--

Mr. Matthew T. Wiley

Chief Commercial Officer

--

Mr. Chris Brinzey

IR Contact Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Robert (Rob) Barrow

Chief Executive Officer, Director

518.46K

+320000.00%

Mr. Mark R. Sullivan

Chief Legal Officer, Corporate Secretary

20.08K

-11276.00%

Dr. Suzanne Louise (Sue) Bruhn, Ph.D.

Independent Director

17.64K

+5402.00%

Dr. Roger Crystal, M.D.

Independent Director

17.64K

+5402.00%

Mr. David W. (Dave) Gryska

Independent Director

10.62K

-9234.00%

Dr. Daniel R. Karlin, M.D.

Chief Medical Officer

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 2月7日週六

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

5.34%

Commodore Capital LP

3.27%

Driehaus Capital Management, LLC

3.16%

Blackstone Alternative Asset Management, L.P.

2.82%

The Vanguard Group, Inc.

2.61%

其他

82.80%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

5.34%

Commodore Capital LP

3.27%

Driehaus Capital Management, LLC

3.16%

Blackstone Alternative Asset Management, L.P.

2.82%

The Vanguard Group, Inc.

2.61%

其他

82.80%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

16.81%

Investment Advisor

13.43%

Hedge Fund

11.26%

Research Firm

1.58%

Individual Investor

1.28%

Private Equity

0.37%

Bank and Trust

0.33%

Pension Fund

0.13%

Venture Capital

0.10%

其他

54.71%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

418

43.37M

44.02%

-6.65M

2025Q3

385

42.65M

43.29%

-5.82M

2025Q2

380

42.59M

55.97%

-6.05M

2025Q1

383

42.99M

56.91%

-5.37M

2024Q4

358

42.80M

58.58%

-14.39M

2024Q3

346

50.91M

62.84%

+1.65M

2024Q2

371

44.11M

63.15%

+4.97M

2024Q1

368

37.27M

54.54%

+28.87M

2023Q4

362

7.25M

18.10%

-366.43K

2023Q3

378

6.32M

16.16%

-494.13K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.26M

5.34%

+38.15K

+0.73%

Sep 30, 2025

Commodore Capital LP

3.23M

3.27%

-1.77M

-35.50%

Sep 30, 2025

Driehaus Capital Management, LLC

3.11M

3.16%

+17.25K

+0.56%

Sep 30, 2025

Blackstone Alternative Asset Management, L.P.

2.78M

2.82%

-810.92K

-22.60%

Sep 30, 2025

The Vanguard Group, Inc.

2.00M

2.03%

+198.88K

+11.04%

Sep 30, 2025

Marshall Wace LLP

2.38M

2.42%

-1.04M

-30.38%

Sep 30, 2025

Octagon Capital Advisors LP

2.13M

2.16%

--

Sep 30, 2025

State Street Investment Management (US)

1.92M

1.95%

+119.00K

+6.59%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.82M

1.85%

+91.25K

+5.26%

Sep 30, 2025

Deep Track Capital LP

1.50M

1.52%

-1.00M

-40.00%

Sep 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

AdvisorShares Psychedelics ETF

9.95%

State Street SPDR S&P Pharmaceuticals ETF

2.17%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.54%

Virtus LifeSci Biotech Clinical Trials ETF

1.32%

iShares U.S. Pharmaceuticals ETF

0.4%

iShares Micro-Cap ETF

0.21%

ProShares Ultra Nasdaq Biotechnology

0.11%

Invesco Nasdaq Biotechnology ETF

0.11%

Nuveen ESG Small-Cap ETF

0.08%

iShares ESG Aware MSCI USA Small-Cap ETF

0.07%

AdvisorShares Psychedelics ETF

佔比9.95%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.17%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.54%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.32%

iShares U.S. Pharmaceuticals ETF

佔比0.4%

iShares Micro-Cap ETF

佔比0.21%

ProShares Ultra Nasdaq Biotechnology

佔比0.11%

Invesco Nasdaq Biotechnology ETF

佔比0.11%

Nuveen ESG Small-Cap ETF

佔比0.08%

iShares ESG Aware MSCI USA Small-Cap ETF

佔比0.07%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

公告日期

除權除息日

類型

比率

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1

Aug 23, 2022

Merger

15→1